SCHEDULE: Sio Capital Management Discloses Stake in PMV Pharmaceuticals

Sio Capital Management, LLC has reported a beneficial ownership of 4.94% in PMV Pharmaceuticals, Inc. as of June 30, 2026.

Summary

• Sio Capital Management, LLC (Sio) has filed a Schedule 13G, indicating a beneficial ownership of 2,634,137 shares of PMV Pharmaceuticals, Inc. common stock.
• This holding represents 4.94% of the class of securities outstanding as of May 12, 2026.
• Sio acts as an investment adviser to affiliated funds that directly hold these shares.
• The filing notes that Michael Castor may be deemed to control the voting and dispositive decisions for these shares.
• The reported ownership is based on information available as of June 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral score as the filing is a routine disclosure of ownership and does not contain operational or financial performance updates for PMV Pharmaceuticals, Inc.

Positives

• Sio Capital Management has disclosed a significant, though just under the 5% threshold, ownership stake, suggesting confidence in PMV Pharmaceuticals' potential.
• The filing is routine and indicates the shares are held in the ordinary course of business, not for the purpose of influencing control.

Negatives

• The ownership stake is just below the 5% threshold that would trigger more detailed Schedule 13D reporting, potentially limiting transparency on Sio's intentions.
• The filing does not provide specific details on the investment strategy or the rationale behind acquiring this stake.

Risks

• The filing does not explicitly mention any risks. However, any investment in a publicly traded company carries inherent market risks.
• Potential for increased scrutiny or influence from Sio Capital Management as they approach or cross the 5% ownership threshold in future filings.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from PMV Pharmaceuticals, Inc. It pertains to Sio Capital Management's ownership stake.

Management Comments

• "Sio Capital Management, LLC beneficially owned 2,634,137 shares of Common Stock with shared voting power and shared dispositive power."
• "Based on 53,331,766 shares of common stock outstanding as of May 12, 2026, as reported in the Issuer's Form 10-Q filed with the SEC on May 12, 2026."
• "Sio and Sio GP, LLC (the "GP") act as investment advisor and general partner, respectively, to various clients that are the record owners of the Common Stock reported on this Schedule 13G."
• "Because Sio's investment discretion with respect to such clients is subject to oversight by the GP, the GP may be deemed to be the beneficial owner of the Common Stock of the Issuer owned by such clients."
• "As such, he may be deemed to control the voting and dispositive decisions with respect to, and therefore be the beneficial owner of, the shares of Common Stock reported on this Schedule 13G."
• "Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by the GP or Michael Castor that such person is the beneficial owner of any of the equity securities referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating stakes in biotechnology and pharmaceutical companies, reflecting active portfolio management within the sector. PMV Pharmaceuticals operates in a highly competitive and capital-intensive industry.

Related Party Transactions

• Sio Capital Management, LLC and Sio GP, LLC are related entities, with Michael Castor potentially controlling both and thus the shares held by clients of Sio.

Stakeholder Impact

• Shareholders: The filing indicates increased institutional interest, which could be perceived positively, but the stake is just below the 5% threshold, offering limited insight into future actions.
• Management of PMV Pharmaceuticals: Aware of a significant institutional holder, potentially influencing future strategic discussions.
• Sio Capital Management clients: Their investments are managed by Sio, with Sio exercising voting and dispositive power over the shares.

Next Steps

• Sio Capital Management will continue to monitor its investment in PMV Pharmaceuticals, Inc.
• Future filings may be required if Sio's ownership stake changes significantly.

Key Dates

Keywords

PMV Pharmaceuticals, Sio Capital Management, Schedule 13G, Beneficial Ownership, Investment Adviser, Common Stock, SEC Filing, Shareholder